Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Christian Lienhardt (Marseille, France). Four-month regimens: are they feasible?. International Congress 2015 – Tuberculosis: short-course chemotherapy

Member's Comments

No comment yet.

Related content which might interest you: Standard IS regimens: CNI is still the cornerstone Source: ERS Course 2016 Year: 2016 Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Positional therapy: easy and effective? Source: Sleep and Breathing Conference 2017 Year: 2017 Intermittent regimens for tuberculosis treatment: Back to the Future? Source: Eur Respir J, 56 (3) 2002510; 10.1183/13993003.02510-2020 Year: 2020 Exercise options post-pulmonary rehabilitation: can we predict patient choice? Source: Annual Congress 2007 - Effects of training in rehabilitation Year: 2007 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 Second- and third-line therapies: what are the best options? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Multimodal therapy in mesothelioma: which modalities are available and useful and how to combine them Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014 More hope for cure by individualised adjuvant treatment? Source: Annual Congress 2010 - Customised chemotherapy for lung cancer Year: 2010 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019